Boston Scientific Corporation (BSX) Earnings Call Analysis

NYSE · Healthcare · Medical Devices

17/25

Growth 3 Margin 3 Expansion 4 Platform 2 Financial 5

latest quarter score

Earnings Reports

17
Boston Scientific (BSX) Q2 2026: Watchman Drops to -7% in H2, Pivots Growth Mix for 2027
July 29, 2026
23
Boston Scientific (BSX) Q4 2025: EP Franchise Soars 35%, Diversification Drives 2026 Visibility
June 15, 2026
18
Boston Scientific (BSX) Q1 2026: Guidance Cut as EP and Watchman Growth Slows, $2B Buyback Signals Capital Confidence
April 22, 2026
23
Boston Scientific (BSX) Q3 2025: Margin Expansion Hits 100bps as Mix and Tariff Offsets Drive Resilience
October 22, 2025
21
Boston Scientific (BSX) Q2 2025: PFA Portfolio Drives Double-Digit Cardiology Growth, Expands Competitive Moat
July 23, 2025
22
Boston Scientific (BSX) Q1 2025: Cardiology Soars 31%, Offsetting $200M Tariff Headwind
July 01, 2025
Boston Scientific (BSX) Q3 2024: EP Sales Surge 177% as PFA Adoption Outpaces Expectations
October 23, 2024
Boston Scientific (BSX) Q2 2024: EP Sales Surge 125% as PFA Adoption Fuels Guidance Raise
July 24, 2024
Boston Scientific (BSX) Q1 2024: Electrophysiology Surges 72%, Raising Full-Year Growth Outlook
April 24, 2024
Boston Scientific (BSX) Q4 2023: Electrophysiology Surges 43% as Farapulse Approval Unlocks Next Growth Leg
January 31, 2024

Browse all companies